Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Hepatocellular Carcinoma (HCC)Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation
Interventions
DRUG

Postoperative adjuvant lenvatinib

Follow the instructions and take lenvatinib 8 mg (body weight ≤ 60Kg) or 12 mg (body weight ≥ 60Kg) orally once a day.

OTHER

Supportive care measures

Adjuvant treatments such as antiviral, TACE, HAIC, radiotherapy, and systemic antitumor therapy can be used

Trial Locations (1)

210029

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
collaborator

The First People's Hospital of Changzhou

OTHER

collaborator

Affiliated Hospital of Nantong University

OTHER

collaborator

Suzhou Municipal Hospital

OTHER

collaborator

Zhongda Hospital

OTHER

collaborator

Northern Jiangsu People's Hospital

OTHER

collaborator

The First People's Hospital of Lianyungang

OTHER

collaborator

The Affiliated Hospital of Xuzhou Medical University

OTHER

collaborator

Xuzhou Central Hospital

OTHER

collaborator

Huai'an First People's Hospital

OTHER

collaborator

Jiangsu Taizhou People's Hospital

OTHER

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER